Abstract | BACKGROUND: METHODS: This was an open-label, non-placebo-controlled, randomized study. A total of 59 patients were randomized to the probucol group (0.5 g, twice daily) or the control group using a 1: 1 treatment ratio. IR was determined using a homeostatic model assessment-IR (HOMA-IR) index. An Excel database was established to analyze follow-up data at weeks 0, 12, and 24. The primary outcome of interest was changes in the HOMA-IR, and the secondary outcomes of interest were changes in the estimated glomerular filtration rate (eGFR), body mass index (BMI), cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein ( LDL), and 24-h urinary protein. RESULTS: The HOMA-IR index of the probucol group after 24 weeks was significantly decreased (P < 0.001) compared to the value before treatment (average decrease: 1.45; range: -2.90 to -0.43). The HOMA-IR index in the control group increased (average increase: 0.54; range: -0.38 to 1.87). For the secondary outcomes of interest, the changes between these two groups also exhibited significant differences in eGFR (P = 0.041), cholesterol (P = 0.001), fasting insulin (P < 0.001), and fasting C-peptide (P = 0.001). CONCLUSIONS:
|
Authors | Rui Wang, Ri-Bao Wei, Yue Yang, Na Wang, Meng-Jie Huang, Cui-Ming Cao, Zi-Cheng Wang, Guang-Yan Cai, Xiang-Mei Chen |
Journal | Journal of geriatric cardiology : JGC
(J Geriatr Cardiol)
Vol. 12
Issue 5
Pg. 521-7
(Sep 2015)
ISSN: 1671-5411 [Print] China |
PMID | 26512244
(Publication Type: Journal Article)
|